Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

Human papillomavirus vaccine in boys: background rates of potential adverse events

- Featured Image

Cervical cancer is the most common cancer affecting women in developing countries. It is caused by persistent infection with specific types of human papillomavirus (HPV).1 Quadrivalent human papillomavirus (4vHPV) vaccine is a recombinant vaccine administered as a three-dose course to provide protection against four types of HPV (6, 11, 16 and 18).2 The vaccine is highly efficacious for the four included types, of which 16 and 18 are reported to cause 70% of cervical cancers and 6 and 11 cause anogenital warts.1,3 4vHPV vaccination was introduced under the Australian National Immunisation Program (NIP) in April 2007 for adolescent girls, with an initial catch-up program including women up to 26 years of age. The current ongoing funded program is only for girls in the first year of high school (aged 12–13 years). Recent data suggest that the 4vHPV vaccination program has caused a rapid decline in genital wart presentations in females,4,5 and there are early indications of a reduction in high-grade cervical dysplasias.

email